Research exploring novel therapies to fight against bladder cancer and a world-first asthma study are among 18 Western projects drawing more than $15 ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of targeted drugs are currently available, including lebrikizumab, dupilumab, and ...

According to a real-world study, tezepelumab is an effective add-on biologic with a rapid onset of action for patients with both T2-high and T2-low severe asthma. The study was published ...

The National Medical Products Administration (NMPA) approved an investigational new drug (IND) application for WIN378 to ...

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") has launched its Phase 2 POLARIS ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The latest UK asthma guidelines1 clearly define the role of Fractional exhaled Nitric Oxide (FeNO) testing in both diagnosing ...

With 118 more biologic drugs set to lose patent protection by 2035, the market for their cheaper mimics could be about to boom.